Dec 19 (Reuters) - BioMarin Pharmaceutical (BMRN) said on Friday it would acquire Amicus Therapeutics (FOLD) for about $4.8 billion, expanding its presence in rare metabolic diseases.
The drugmaker will pay $14.50 per share for Amicus, a premium of 33.1% to the stock's last close. Shares of Amicus surged 30%, while BioMarin rose nearly 5% in premarket trading.
The deal strengthens BioMarin's portfolio with Amicus' approved genetic disorder treatments including Galafold, an oral drug for Fabry disease, which is caused by a faulty gene that leads to a buildup of fatty substances in cells.
Amicus also markets a combination therapy Pombiliti and Opfolda for Pompe disease, a genetic condition in which a complex sugar called glycogen builds up in the body's cells.
Amicus also has U.S. rights to DMX-200, a potential treatment of a type of kidney disease known as focal segmental glomerulosclerosis.
BioMarin intends to finance the deal through a combination of cash on hand and about $3.7 billion of non-convertible debt financing.
The company's total cash and investments at the end of September 30 were about $2 billion.
The acquisition, which is expected to close in the second quarter of 2026, will add revenue immediately after the transaction closes, BioMarin said.
The deal is also expected to add to adjusted profit in the first 12 months after close and be substantially accretive beginning in 2027, the company said.
(Reporting by Christy Santhosh and Sriparna Roy in Bengaluru; Editing by Leroy Leo and Maju Samuel)
latest_posts
- 1
Like many holiday traditions, lighting candles and fireplaces is best done in moderation - 2Step by step instructions to Recognize the Distinction Between Lab Jewels and Precious stone Simulants
- 3Holiday weather forecast: Where travelers can expect a wintry mix, flooding and record warmth across the U.S.
- 45 Wellbeing Applications Assist You With remaining Fit
- 5The Green Transformation: 5 Feasible Living Practices
- 'Set up an Army Radio station at President’s Residence': Source close to Katz slams Herzog
- Russia accidentally destroys its only way of sending astronauts to space
- Most loved Amusement Park for Small children: Which One Do You Suggest?
- Glamour Shots once ruled the mall. I went to one of the last ones standing.
- 5 Most Expected Film Delivery
- A Manual for Extravagant Vehicles Available in 2024
- Israeli strikes in Gaza kill 25 people, Hamas health authority says
- The 10 Most Famous Works of art Ever
- Social Skylines d: A Survey of \Inside and out Social Experiences\ Language Learning Book
